NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/11/2023
Back to search
Official data from USPTO
DERMPHI THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
07/11/2023
Trademark type
Combined
Nice classes
3, 5
Filing date
02/11/2022
Registration date
07/11/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/11/2023
Last transaction
07/11/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
Calgary, Alberta, CA
Examiner
PRIZANT, JAMES
Law office
O10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of an upper case Greek alphabet letter meaning "phi" above the word "DERMPHI" where the word "DERMPHI" is positioned directly above the word "THERAPEUTICS".
Holders and representatives
Holders
Dermphi Therapeutics Inc.
Representatives
B. Anna McCoy MCCOY RUSSELL LLP
Technical classification
Nice Classes
Class 3Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 3
Beauty care cosmetics; face and body lotions; body creams; sunscreen preparations
Class 5
Dietary supplements for general health and well-being; vitamins; nutritional supplements for general health and well-being; medicated skin care preparations for use in the treatment of acnecomedonesalopeciaeczemaxerosisdiaper dermatitisirritant contact dermatitisseborrheic dermatitisichthyosiskeratosis pilarishyperpigmentationmelasmamolluscum contagiosumpruritusitchingfungal nail infectionswartspsoriasisrosaceasolar lentigoscarsstretch marks and wrinkles; pharmaceutical preparations for use in dermatologyfor use in the treatment of acnecomedonesalopeciaeczemaxerosisdiaper dermatitisirritant contact dermatitisseborrheic dermatitisichthyosiskeratosis pilarishyperpigmentationmolluscum contagiosumpruritusitchingfungal nail infectionswartspsoriasisskin pigmentation diseasesmelasmasolar lentigorosaceascarsstretch marks and wrinkles
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/25/2023
PUBO
PUBLISHED FOR OPPOSITION
04/25/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/05/2023
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
03/20/2023
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
03/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/09/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/06/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/05/2022
GNRT
NON-FINAL ACTION E-MAILED
12/05/2022
CNRT
NON-FINAL ACTION WRITTEN
12/05/2022
DOCK
ASSIGNED TO EXAMINER
11/27/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
02/17/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/16/2022
NWAP
NEW APPLICATION ENTERED
02/15/2022
Continuous trademark protection
Get notified about every new filing that threatens DERMPHI THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.